CRL

174.90

1.39% 2.40

Handel nachbörslich: 174.90

Charles River Laboratories International Inc (CRL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$172.50

Offen:

$173.77

24-Stunden-Volumen:

915.70K

Relative Volume:

0.97

Marktkapitalisierung:

$8.61B

Einnahmen:

$4.02B

Nettoeinkommen (Verlust:

$-142.16M

KGV:

-59.16

EPS:

-2.9563

Netto-Cashflow:

$518.49M

1W Leistung:

+5.43%

1M Leistung:

-2.01%

6M Leistung:

+2.59%

1J Leistung:

+19.80%

1-Tages-Spanne:

$171.66

$176.20

1-Wochen-Bereich:

$153.25

$176.20

52-Wochen-Spanne:

$91.86

$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Firmenname

Charles River Laboratories International Inc

Sektor

Healthcare (1116)

Branche

Diagnostics & Research (52)

Telefon

781-222-6000

Adresse

251 BALLARDVALE ST, WILMINGTON, MA

Mitarbeiter

19,700

Twitter

@criverlabs

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, WAT

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRL Charles River Laboratories International Inc	174.90	8.49B	4.02B	-142.16M	518.49M	-2.9563
TMO Thermo Fisher Scientific Inc	494.54	182.60B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	190.79	134.18B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	564.66	44.63B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.54	32.21B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	299.89	29.21B	3.17B	642.63M	516.49M	10.77

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-15	Hochstufung	BofA Securities	Neutral → Buy
2025-11-17	Hochstufung	Argus	Hold → Buy
2025-11-06	Hochstufung	Robert W. Baird	Neutral → Outperform
2025-10-06	Hochstufung	William Blair	Mkt Perform → Outperform
2025-10-02	Hochstufung	Barclays	Equal Weight → Overweight
2025-09-09	Hochstufung	Jefferies	Hold → Buy
2025-07-09	Hochstufung	Citigroup	Neutral → Buy
2025-05-23	Hochstufung	Redburn Atlantic	Neutral → Buy
2025-05-14	Hochstufung	TD Cowen	Hold → Buy
2025-05-08	Hochstufung	Evercore ISI	In-line → Outperform
2025-03-21	Herabstufung	Goldman	Buy → Neutral
2025-03-04	Hochstufung	Citigroup	Sell → Neutral
2025-03-03	Hochstufung	Redburn Atlantic	Sell → Neutral
2025-01-22	Herabstufung	William Blair	Outperform → Mkt Perform
2025-01-17	Herabstufung	UBS	Buy → Neutral
2024-11-18	Herabstufung	CLSA	Hold → Underperform
2024-11-07	Hochstufung	CLSA	Underperform → Hold
2024-10-23	Eingeleitet	CLSA	Underperform
2024-10-14	Eingeleitet	Redburn Atlantic	Sell
2024-10-07	Herabstufung	Evercore ISI	Outperform → In-line
2024-10-02	Herabstufung	BofA Securities	Buy → Neutral
2024-10-01	Herabstufung	Citigroup	Neutral → Sell
2024-08-08	Herabstufung	JP Morgan	Overweight → Neutral
2024-08-08	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-06-28	Herabstufung	Argus	Buy → Hold
2024-06-07	Eingeleitet	Mizuho	Neutral
2024-06-06	Eingeleitet	Goldman	Buy
2024-02-15	Herabstufung	Guggenheim	Buy → Neutral
2023-09-13	Eingeleitet	TD Cowen	Market Perform
2023-07-10	Herabstufung	Citigroup	Buy → Neutral
2023-02-23	Hochstufung	Guggenheim	Neutral → Buy
2023-01-12	Herabstufung	Jefferies	Buy → Hold
2022-09-30	Hochstufung	Jefferies	Hold → Buy
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-08-04	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	Eingeleitet	Guggenheim	Neutral
2022-04-25	Herabstufung	Jefferies	Buy → Hold
2022-04-07	Eingeleitet	Stephens	Overweight
2022-02-17	Bestätigt	BofA Securities	Buy
2022-02-17	Hochstufung	Citigroup	Neutral → Buy
2022-02-17	Bestätigt	Deutsche Bank	Buy
2022-02-17	Bestätigt	Morgan Stanley	Overweight
2022-02-17	Bestätigt	UBS	Buy
2021-08-05	Fortgesetzt	Credit Suisse	Neutral
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-09-10	Hochstufung	Jefferies	Hold → Buy
2020-07-01	Hochstufung	BofA Securities	Neutral → Buy
2020-05-13	Hochstufung	UBS	Neutral → Buy
2020-04-21	Herabstufung	Jefferies	Buy → Hold
2020-03-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	Eingeleitet	Deutsche Bank	Buy
2020-02-18	Hochstufung	Wolfe Research	Peer Perform → Outperform
2020-01-10	Hochstufung	Goldman	Neutral → Buy
2020-01-08	Eingeleitet	Wells Fargo	Overweight
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-18	Herabstufung	BofA/Merrill	Buy → Neutral
2019-06-10	Eingeleitet	SVB Leerink	Outperform
2019-04-30	Fortgesetzt	Evercore ISI	Outperform
2018-12-14	Eingeleitet	Deutsche Bank	Buy
2018-10-09	Eingeleitet	UBS	Neutral
2018-08-23	Hochstufung	Raymond James	Mkt Perform → Outperform
2018-07-17	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	Hochstufung	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	Hochstufung	SunTrust	Hold → Buy

Alle ansehen

Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten

Apr 01, 2026

Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Apr 01, 2026

CRL Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 01, 2026

Mar 31, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN

Mar 31, 2026

AI-led selloff in contract research firms may be misjudging disruption risk - Reuters

Mar 31, 2026

[ARS] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filing - Stock Titan

Mar 31, 2026

Charles River (NYSE: CRL) details CEO transition, 4.8M-share incentive plan in 2026 proxy - Stock Titan

Mar 31, 2026

Allspring Global Investments Holdings LLC Cuts Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat

Mar 31, 2026

Charles River Laboratories Stock: A Key Player in Drug Discovery Services for North American Investo - AD HOC NEWS

Mar 31, 2026

Mar 30, 2026

Valuation Update: Will Charles River Laboratories International Inc benefit from green energy policies2026 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Mar 30, 2026